Mammary Cell News 11.17 May 9, 2019 | |
| |
TOP STORYScientists demonstrated that the type II keratin topological associating domain underwent epigenetic reprogramming in aromatase inhibitor-resistant cells, leading to keratin-80 (KRT80) upregulation. KRT80 expression was driven by de novo enhancer activation by sterol regulatory element-binding protein 1. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers report a noncanonical role of CBFB in translation regulation. RNA immunoprecipitation followed by deep sequencing revealed that cytoplasmic CBFB bound to hundreds of transcripts and regulated their translation. [Nat Commun] Full Article Metabolically Activated Adipose Tissue Macrophages Link Obesity to Triple-Negative Breast Cancer Metabolically activated phenotype macrophages released IL-6 in an NADPH oxidase 2-dependent manner, which signaled through glycoprotein 130 on triple-negative breast cancer cells to promote stem-like properties including tumor formation. [J Exp Med] Abstract | Press Release | Graphical Abstract Investigators characterized a novel long noncoding RNA (lncRNA), RP1-5O6.5 (termed as RP1). Gain-of-function and loss-of-function assays showed that RP1 promoted the proliferation and metastasis of breast cancer cells in vitro and in vivo. [Cell Death Dis] Full Article The authors applied a machine-learning-based approach (idTRAX) to triple-negative breast cancer cell lines and efficiently identified cancer-selective targets. They found that inhibiting AKT selectively killed MFM-223 and CAL148 cells, while inhibiting FGFR2 only killed MFM-223. [Cell Chem Biol] Abstract | Graphical Abstract Researchers assessed the suitability of laser ablation-inductively coupled plasma-mass spectrometry as a micro-analytical technique for the localization and quantification of membranous receptors in heterogeneous cell samples that expressed both the membrane-bound receptors C-X-C chemokine receptor type 4 and epidermal growth factor receptor. [Anal Chim Acta] Abstract | Graphical Abstract The authors classified cell lines as CB-839 sensitive or resistant according to their growth responses to CB-839. Compared with sensitive cells, resistant cells were less glutaminolytic and, upon CB-839 treatment, exhibited a smaller decrease in ATP content and less mitochondrial fragmentation, an indicator of poor mitochondrial health. [J Biol Chem] Abstract | Full Article Scientists demonstrated that autophagy involvement behind the antiproliferative action of a ruthenium(III)-complex incorporated into a cationic nanosystem proved to be hitherto one of the most effective within the suite of nucleolipidic formulations they developed for the in vivo transport of anticancer ruthenium(III)-based drugs. [Sci Rep] Full Article VANGL2 Regulates Luminal Epithelial Organization and Cell Turnover in the Mammary Gland Investigators utilized a panel of Vang1 and Vangl2 mouse alleles to examine the requirement of VANGL family members in the murine mammary gland. They showed that Vang1CKOΔ/Δ glands displayed normal branching while Vangl2flox/flox and Vangl2Lp/Lp tissue exhibited several phenotypes. [Sci Rep] Full Article Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSMechanisms of Genomic Instability in Breast Cancer The authors comprehensively discuss the recent advances on the mechanisms of genomic instability (GI) in breast cancer, highlighting DNA repair defects and chromosome segregation errors during mitosis. They further review the clinical implications and therapeutic potential of targeting GI in the era of precision medicine. [Trends Mol Med] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
SCIENCE NEWSSermonix Pharmaceuticals LLC announced that it will present a poster on the performance of its lead investigational drug, lasofoxifene. [Press release from Sermonix Pharmaceuticals LLC discussing research to be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release | |
| |
INDUSTRY NEWSDaiichi Sankyo Company, Limited and AstraZeneca announced positive topline results for the pivotal Phase II DESTINY-Breast01 trial of [fam-] trastuzumab deruxtecan. The HER2 targeting antibody drug conjugate was evaluated in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine. [Daiichi Sankyo Company, Ltd] Press Release Cotinga Pharmaceuticals Inc. announced that the company has released early interim data of its ongoing Phase Ib/IIa clinical trial of COTI-2 plus cisplatin in solid tumors. [Cotinga Pharmaceuticals, Inc. (GlobeNewswire, Inc.)] Press Release Onxeo S.A. announces a new milestone in the clinical development of AsiDNA™ with the treatment of the first patient in DRIIV-Ib, a phase Ib clinical study of AsiDNA™, a first-in-class tumor DNA repair inhibitor, in combination with carboplatin and with carboplatin plus paclitaxel, in patients with solid tumors eligible to such treatments. [Onxeo S.A.] Press Release CytoDyn Inc. announced that in a murine xenograft human breast cancer metastatic model, after nine weeks, compared with untreated mice at eight weeks, the leronlimab treated mice continued to have a >98% reduction in metastatic burden. [CytoDyn, Inc.] Press Release Genentech announced that the FDA has approved Kadcyla® for adjuvant treatment of people with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and Herceptin®-based treatment. [Genentech, Inc.] Press Release CytoDyn Inc. announced that the FDA has granted Fast Track Designation to leronlimab for use in combination with carboplatin for the treatment of patients with CCR5-positive metastatic triple-negative breast cancer. [CytoDyn, Inc.] Press Release | |
| |
POLICY NEWSWhite House to Convene Committee to Address Research Obstacles The leaders of the White House Office of Science and Technology, National Institutes of Health, National Science Foundation, National Institute of Standards and Technology, and the Department of Energy’s science division have formed a committee “to address issues facing the US research community,” President Donald Trump’s administration announced. [The Scientist] Editorial Black Academics Publish One-Fifth of South Africa’s Research The proportion of scientific articles published by academics in South Africa who are black, colored or of Indian origin has risen almost tenfold since the end of apartheid, to about one-third, finds a report on scholarly publishing in the country. [Nature News] Editorial
| |
EVENTSNEW European Society for Medical Oncology (ESMO) 2019 Congress Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Assistant – Anti-Breast Cancer Drugs (United Arab Emirates University) Postdoctoral Fellowship – PcG-Mediated Mechanisms in Breast Cancer (University of Miami) Postdoctoral Research Position – Molecular Biology & Cancer Research (Augusta University) Postdoctoral Fellowship – Tumor Suppressor CSMD1 (Lund University) Postdoctoral Position – Breast Cancer Research (Massachusetts General/Harvard Medical School) Faculty Position – Breast and Ovarian Cancer (Fred Hutchinson Cancer Research Center) Postdoctoral Fellowship – Breast Cancer Research (Washington University School of Medicine) Professor – Breast Cancer (University Hospitals Cleveland Medical Center) Postdoctoral Associate – Cancer Immunology (The Jackson Laboratory) Postdoctoral Fellow – Cancer Bioinformatics (BC Cancer Research Center, PHSA) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|